Enliven Therapeutics ELVN Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Enliven Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The official record: Enliven Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Enliven Therapeutics's financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Enliven Therapeutics's financing cash flow?
- Enliven Therapeutics (ELVN) reported financing cash flow of $10.05M in Q1 2026.
- How has Enliven Therapeutics's financing cash flow changed year-over-year?
- Enliven Therapeutics's financing cash flow increased by 4196.2% year-over-year, from $234K to $10.05M.
- What is the long-term trend for Enliven Therapeutics's financing cash flow?
- Over 3 years (2021 to 2025), Enliven Therapeutics's financing cash flow has grown at a 64.7% compound annual growth rate (CAGR), from $49.11M to $219.24M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.